Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Inventiva, retaining the price target of $20.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Edward Nash has given his Buy rating due to a combination of factors surrounding Inventiva’s promising developments and strategic positioning. The company’s pan-PPAR agonist, lanifibranor, is currently in Phase III development with the NATiV3 clinical trial, targeting patients with F2/F3 MASH. The anticipated top-line data from this trial, expected in the second half of 2026, is a significant catalyst, as the trial aims to meet dual primary endpoints of fibrosis improvement and MASH resolution, which are critical for regulatory approval.
Moreover, the mechanism of action of lanifibranor positions it well to address multiple aspects of the disease, particularly in patients with both MASH and Type 2 Diabetes (T2D). This patient group is considered a strategic target due to the lack of other investigational agents specifically designed for them and their higher cardiovascular risk profile. These factors, combined with the company’s confidence in meeting trial endpoints, underpin Nash’s optimistic outlook and Buy rating for Inventiva.
According to TipRanks, Nash is a 5-star analyst with an average return of 14.9% and a 45.35% success rate. Nash covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Cardiol Therapeutics, and Madrigal Pharmaceuticals.